Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.

January 19, 2026 updated by: Raafat R. Mohammed, Benha University

Composite Inflammatory Parameters Ratios Enforce the Role of CRP for Monitoring Ulcerative Colitis Disease Activity

Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition marked by disturbed levels of various hematological inflammatory cells and a deregulated immune environment. While C-reactive protein (CRP) is a key acute-phase reactant, its high levels can persist even after inflammation subsides. Other simple, cost-effective ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), and Albumin-related ratios, also serve as promising, reproducible markers of systemic inflammation reflecting both immune status and nutrition. This study's objective is to evaluate the diagnostic performance of these various hematological inflammatory cellular components and CRP-related ratios (like the CAR) as predictors for Ulcerative Colitis (UC) disease severity, using colonoscopic and microscopic findings as the gold standard for comparison.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • El Alexandria
      • Alexandria, El Alexandria, Egypt, 21512
        • Alexandria Faculty of medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consisted of all patients exhibiting clinical signs suggestive of Inflammatory Bowel Disease were assessed for Ulcerative Colitis diagnostic criteria.

Description

Inclusion Criteria:

  • Patients who fulfilled the diagnostic criteria for UC;
  • Patients were free of exclusion criteria;
  • Patients who signed the written consent were enrolled in the study

Exclusion Criteria:

  • Patients who was Previously diagnosed with IBD or IBS;
  • Patients with recurrence of manifestations after surgical resection;
  • Patients who refused to sign the participation consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Ulcerative Colitis Patients
Patients exhibiting clinical signs suggestive of IBD were assessed for UC diagnostic criteria, and the study inclusion and exclusion standards.
Diagnostic test: C-Reactive Protein measuring CRP
5-ml peripheral blood samples were aseptically obtained for a complete blood count, and ELISA estimation of serum CRP
Diagnostic test: CRP to Albumin Ratio
Serum CRP to albumin ratio (CAR) is a combination of markers for systemic inflammation and nutritional status

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Correlation Between Clinical and Endoscopic Diagnostic Indices and Hematologic Ratios
Time Frame: 45 days
Evaluating the role of diagnostic indices (Ulcerative Colitis Disease Activity Index (UC-DAI), Simple Clinical Colitis Activity Index (SCCAI), Fecal Calprotectin (FCP) ≥150μg/ml) in active Ulcerative Colitis (UC) and their correlation with novel hematologic inflammatory markers, including Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Inflammatory Response Index (SIRI), Systemic Inflammation Index (SII), and the serum C-Reactive Protein (CRP)-to-Albumin Ratio (CAR).
45 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Benha University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2025

Primary Completion (Actual)

November 25, 2025

Study Completion (Actual)

December 1, 2025

Study Registration Dates

First Submitted

November 22, 2025

First Submitted That Met QC Criteria

November 22, 2025

First Posted (Actual)

December 3, 2025

Study Record Updates

Last Update Posted (Actual)

January 21, 2026

Last Update Submitted That Met QC Criteria

January 19, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E/C. S/N. R14/2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ulcerative Colitis

Clinical Trials on C-Reactive Protein measuring CRP

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe